Asian Capabilities

Asian Capabilities

International deal-making has long been a goal of maximizing value in the biopharma landscape. Navigating cultural norms, understanding reimbursement and regulatory protocols and assessing market opportunity can be daunting for clients who wish to partner in ex-US territories, particularly in Asia. We have found that executing a well-defined deal strategy for Asia enables clients to raise non-dilutive capital, maximize asset value and retain rights in their domestic markets.  We are fortunate to have the hands-on deal and operating expertise to offer clients the following:

  • Sell-side regional deal processes allow clients to realize value from their asset outside their domestic
  • Buy-side sourcing adds to a growth biopharma’s deal flow that is below the radar
  • Private financing from Asian investors who are increasingly interested in investing in US/foreign companies

Meet our Managing Director for Asia, Steve Engen. Steve brings over 20 years of executive-level experience, the majority of which has been spent in Japan/Asia. He is fluent in Japanese and is able to gain access to criticial decision-makers in Japanese/Asian biopharmacticeutical companies.

 

Asian Capabilities Transaction Highlights

CLIENT: Pieris

PARTNER: ASKA Pharmaceutical

TRANSACTION:
Sell-side Japan/Asia collaboration for PRS-080

View Case Study>>

MedgenicsKHK

CLIENT: Medgenics, Inc.

PARTNER: Kyowa Hakko Kirin

TRANSACTION:
Leveraging relationships in Japan to facilitate collaboration to develop and commercialize KHK’s anti-LIGHT mAb.

View case study »

logos

CLIENT: Regeneron

PARTNER: Mitsubishi Tanabe Pharma

TRANSACTION:
Facilitating negotiations between US and Japan to speed deal execution.

View case study »

Logos

CLIENT: Armetheon

PARTNER: Lees Pharma

TRANSACTION:
Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand

View case study »

Locust_Concordian_Ono

CLIENT: Concordia Pharmaceuticals

PARTNER: Ono

TRANSACTION:

Licensing Agreement for Salirasib in Japan

View case study »